LncRNA H19: a novel player in the regulation of diabetic kidney disease

Wu, Qinrui; Huang, Fengjuan

doi:10.3389/fendo.2023.1238981

Cited by 3 publications

(1 citation statement)

References 170 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Diabetes can cause various serious and some life-threatening complications ( Popoviciu et al., 2023 ). Diabetic nephropathy (DN) is one of the common microvascular complications, characterized by structural and functional damage to the kidneys ( Wu and Huang, 2023 ). Clinical manifestations include massive proteinuria, hypertension, and edema, and it is one of the main causes of end-stage renal disease (ESRD) ( Wu et al., 2023 ).…”

Section: Introductionmentioning

confidence: 99%

Gut microbiota microbial metabolites in diabetic nephropathy patients: far to go

Yu,

Chen,

Zang

et al. 2024

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Diabetic nephropathy (DN) is one of the main complications of diabetes and a major cause of end-stage renal disease, which has a severe impact on the quality of life of patients. Strict control of blood sugar and blood pressure, including the use of renin–angiotensin–aldosterone system inhibitors, can delay the progression of diabetic nephropathy but cannot prevent it from eventually developing into end-stage renal disease. In recent years, many studies have shown a close relationship between gut microbiota imbalance and the occurrence and development of DN. This review discusses the latest research findings on the correlation between gut microbiota and microbial metabolites in DN, including the manifestations of the gut microbiota and microbial metabolites in DN patients, the application of the gut microbiota and microbial metabolites in the diagnosis of DN, their role in disease progression, and so on, to elucidate the role of the gut microbiota and microbial metabolites in the occurrence and prevention of DN and provide a theoretical basis and methods for clinical diagnosis and treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Gut microbiota microbial metabolites in diabetic nephropathy patients: far to go

Yu,

Chen,

Zang

et al. 2024

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

show abstract

Exploring Therapeutic Potential of Nutraceutical Compounds from Propolis on MAPK1 Protein Using Bioinformatics Approaches as Anti-Coronavirus Disease 2019 (COVID-19)

Siregar,

Kustiawan,

Sari

et al. 2024

BIO Web Conf.

View full text Add to dashboard Cite

This study explores the potential of propolis, a natural substance, as a gene therapy for treating COVID-19. Despite the advent of COVID-19 vaccines, their side effects pose new health challenges. Utilizing network pharmacology, this research identifies propolis compounds through various databases and assesses their ability to target proteins associated with COVID-19. MAPK1 emerges as a potential therapeutic target, and molecular docking reveals Broussoflavonol F, Glyasperin A, and Sulabiroins as promising compounds with strong binding affinities, i.e.,- 9.0, -9.0, and -8.8 kcal/mol, respectively, exceeding the native ligand (-7.2 kcal/mol). Molecular Dynamics displays stable complex behavior, with backbone RMSD values consistently below 4 Angstroms and RMSF simulations showing minimal fluctuations within ±2 Angstroms error. Moreover, MM-PBSA analysis further supports the strong binding of Broussoflavonol F, Glyasperin A, and Sulabiroins A, with relative binding energies of -122.82±89.65, 131.48±95.39, and -155.97±111,37 kJ/mol, respectively. These results indicate that propolis has potential as an anti-COVID-19 agent, primarily through inhibiting the MAPK1 pathway. However, further research is needed to validate these results and develop practical applications for COVID-19 therapy. This study underscores the significance of network pharmacology and computational models in understanding propolis mechanisms, offering potential directions for future research and treatment strategies against COVID-19.

show abstract

Long Non-Coding RNAs in Kidney Injury: A Comprehensive Review

Bhat,

Shanbhag

2024

JPDMHD

View full text Add to dashboard Cite

Kidney injury, a global health challenge, necessitates a nuanced understanding of molecular intricacies for effective interventions. Long non-coding RNAs (lncRNAs), once dismissed as transcriptional noise, now emerge as pivotal players in orchestrating renal health. Dysregulation of specific lncRNAs like TUG1, MALAT1, H19, and NEAT1 provides molecular signatures, distinguishing physiological states from pathological conditions. In acute kidney injury (AKI), TUG1 and MALAT1 regulate apoptosis, inflammation, and fibrosis. Chronic kidney disease (CKD) involves lncRNAs like H19 and NEAT1 modulating cell proliferation and apoptosis. Beyond diagnostics, lncRNAs actively shape inflammation, apoptosis, and fibrosis, positioning them as master regulators in the intricate ballet of kidney health. Recent strides in research, coupled with cutting-edge genomics and bioinformatics tools, highlight their roles and therapeutic potential. Challenges in understanding their intricate roles and interactions necessitate the exploration of promising avenues, including single-cell RNA sequencing and artificial intelligence, paving the way for personalized interventions and regenerative medicine in kidney diseases.

show abstract

LncRNA H19: a novel player in the regulation of diabetic kidney disease

Cited by 3 publications

References 170 publications

Gut microbiota microbial metabolites in diabetic nephropathy patients: far to go

Gut microbiota microbial metabolites in diabetic nephropathy patients: far to go

Exploring Therapeutic Potential of Nutraceutical Compounds from Propolis on MAPK1 Protein Using Bioinformatics Approaches as Anti-Coronavirus Disease 2019 (COVID-19)

Long Non-Coding RNAs in Kidney Injury: A Comprehensive Review

Contact Info

Product

Resources

About